2,109 reports of this reaction
5.9% of all ABEMACICLIB reports
#2 most reported adverse reaction
FATIGUE is the #2 most commonly reported adverse reaction for ABEMACICLIB, manufactured by Eli Lilly and Company. There are 2,109 FDA adverse event reports linking ABEMACICLIB to FATIGUE. This represents approximately 5.9% of all 35,479 adverse event reports for this drug.
Patients taking ABEMACICLIB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among ABEMACICLIB users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for ABEMACICLIB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 2,109 FDA reports for ABEMACICLIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 5.9% of all adverse event reports for ABEMACICLIB, making it one of the most commonly reported side effect.
If you experience fatigue while taking ABEMACICLIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.